In Vitro Development of Resistance to Human Immunodeficiency Virus Protease Inhibitor GW640385

Documenti analoghi

• In Vitro Antiviral Activity of the Novel, Tyrosyl-Based Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor Brecanavir (GW640385) in Combination with Other Antiretrovirals and against a Panel of Protease Inhibitor-Resistant HIV
  di: Hazen, Richard, et al.
  Pubblicazione: (2007)
• Anti-Human Immunodeficiency Virus Type 1 Activity of the Nonnucleoside Reverse Transcriptase Inhibitor GW678248 in Combination with Other Antiretrovirals against Clinical Isolate Viruses and In Vitro Selection for Resistance
  di: Hazen, Richard J., et al.
  Pubblicazione: (2005)
• In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632
  di: Gong, Yi-Fei, et al.
  Pubblicazione: (2000)
• Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir
  di: Furfine, Eric S., et al.
  Pubblicazione: (2004)
• Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors
  di: Maguire, Michael, et al.
  Pubblicazione: (2002)